Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:46 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Still Disease Clear all
Completed Phase 3 Interventional Results available

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT00889863
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions
canakinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Nov 2, 2026, 9:46 PM EST
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

NCT03265132
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
Interventions
anakinra, Placebo
Biological · Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Nov 2, 2026, 9:46 PM EST
Not yet recruiting No phase listed Observational

Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.

NCT07909005
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
Interventions
Local laboratory testing, Local Lab Tests
Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Up to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Terminated Phase 1 Interventional

A Study to Evaluate Camoteskimab in Participants With Still's Disease

NCT04752371
View directory record Official record
Conditions
Adult Onset Still's Disease
Interventions
Camoteskimab (CERC-007, AVTX-007, AEVI-007)
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Nov 2, 2026, 9:46 PM EST
Terminated Phase 1 Interventional

Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors

NCT00866086
View directory record Official record
Conditions
Lung Cancer
Interventions
questionnaire administration, computed tomography, radiation therapy treatment planning/simulation
Other · Procedure · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Nov 2, 2026, 9:46 PM EST
Enrolling by invitation Phase 2 Interventional

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

NCT05669989
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 1 Interventional

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT01455701
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 24 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Nov 2, 2026, 9:46 PM EST
Completed No phase listed Observational Accepts healthy volunteers

BioThrax® (Anthrax) Vaccine in Pregnancy Registry

NCT01653392
View directory record Official record
Conditions
Pregnancy Complications, Pregnancy Outcome, Congenital Abnormalities
Interventions
Observational Intervention
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Nov 2, 2026, 9:46 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.

NCT03174574
View directory record Official record
Conditions
Pancreas Cancer, Melanoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 2 Interventional Results available

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

NCT00152503
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (UCB44212)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Nov 2, 2026, 9:46 PM EST
Recruiting No phase listed Observational

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

NCT07330258
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Standard of Care
Other
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults

NCT00534495
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Rilonacept
Biological
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Months to 19 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Nov 2, 2026, 9:46 PM EST
Recruiting Phase 2 Interventional

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

NCT07203001
View directory record Official record
Conditions
Still´s Disease
Interventions
MAS825
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Cincinnati, Ohio • Portland, Oregon • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 3 Interventional Results available

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

NCT00833703
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Nov 2, 2026, 9:46 PM EST
Completed No phase listed Observational

Assessment of Macrophage Activation syndromE in STill's Disease

NCT06405152
View directory record Official record
Conditions
Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
Interventions
Chart review
Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
6 Months to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 1 Interventional

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

NCT01904292
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 3 Interventional Results available

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

NCT05001737
View directory record Official record
Conditions
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
6 Months to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Recruiting Not applicable Interventional

Obstructive Sleep Apnea Therapeutic Intervention for REsiDual Sleepiness

NCT06698809
View directory record Official record
Conditions
Obstructive Sleep Apnea, Sleepiness
Interventions
Active tPBM
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 2 Interventional Results available

Interleukin-1 Trap to Treat Autoinflammatory Diseases

NCT00094900
View directory record Official record
Conditions
Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
Interventions
IL-1 Trap
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Nov 2, 2026, 9:46 PM EST
Recruiting Not applicable Interventional

Placental Imaging Techniques

NCT06861309
View directory record Official record
Conditions
Fetal Growth Restriction (FGR), Placental Insufficiency, Preeclampsia, Still Births, Pregnancy, Pregnancy Complications, Pregnancy Outcomes, Ultrasound
Interventions
ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS)
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Introduction and Maintenance of Still Eating Protein Blends in Support of Infant Nutritional Goals

NCT03667118
View directory record Official record
Conditions
Food Allergy
Interventions
Food Supplement
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
5 Months to 11 Months
Enrollment
705 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 3 Interventional Results available

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

NCT03000439
View directory record Official record
Conditions
Arthritis Juvenile Idiopathic
Interventions
In open-label phase: treatment with tofacitinib, In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Nov 2, 2026, 9:46 PM EST
Recruiting No phase listed Observational

Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.

NCT07845942
View directory record Official record
Conditions
Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis Associated Lung Disease
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 2, 2026, 9:46 PM EST